wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9C
Q33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9C
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
P2860
Q33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33399867-E2623D51-6B13-42D7-91F7-E4E05F12BD9C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
88f3cd06f84f1d95ed0fecfd6c03b5a1934438f9
P2860
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.